BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
©The Author(s) 2025.
World J Clin Oncol. Dec 24, 2025; 16(12): 112443
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.112443
Figure 4
Figure 4 Overall survival by neoadjuvant chemotherapy in patients with peritoneal metastases. A: In synchronous peritoneal metastases (PM), median overall survival (OS) was longer with neoadjuvant treatment (28.0 months vs 16.0 months), though not statistically significant; B: In metachronous PM, OS was similar regardless of neoadjuvant therapy. PM: Peritoneal metastases; OS: Overall survival; CHT: Chemotherapy.


Write to the Help Desk